[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353789-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353789-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fibroblast-growth-factor-receptor-fgfr-inhibitors-for-the-treatment-of-cholangiocarcinoma-key-therapeutic-developments-and-knowledge-gaps","Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma - Key Therapeutic Developments and Knowledge Gaps","","Fibroblast growth factor receptor 2 (FGFR2) alterations have emerged as an important targetable oncogenic driver in a biologically distinct subset of biliary tract cancers, particularly intrahepatic cholangiocarcinoma (iCCA), alongside other actionable genomic events. FGFR2 fusions and mutations define a molecular subgroup with geographic variability and distinct etiologic contexts. Reversible and irreversible FGFR inhibitors show meaningful activity in FGFR2-rearranged iCCA, with on-target hyperphosphataemia as a characteristic toxicity. cfDNA liquid biopsy maps secondary kinase-domain mutations driving acquired resistance, guiding next-generation FGFR2-selective inhibitors and EGFR/ERBB blockade combinations. These findings support comprehensive molecular profiling and innovative umbrella trials to optimize targeted therapy in this rare malignancy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fibroblast-growth-factor-receptor-fgfr-inhibitors-for-the-treatment-of-cholangiocarcinoma-key-therapeutic-developments-and-knowledge-gaps/353789/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fibroblast-growth-factor-receptor-fgfr-inhibitors-for-the-treatment-of-cholangiocarcinoma-key-therapeutic-developments-and-knowledge-gaps/353789.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes FGFR2 alterations important in biliary tract cancers?","Question",{"text":63,"@type":64},"FGFR2 alterations function as a targetable oncogenic driver in a biologically distinct subset of biliary tract cancers, especially intrahepatic cholangiocarcinoma (iCCA). FGFR2 fusions and mutations define a specific molecular subgroup.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How have FGFR inhibitors performed in FGFR2-rearranged iCCA?",{"text":68,"@type":64},"Clinical studies of reversible and irreversible FGFR inhibitors demonstrate meaningful activity in FGFR2-rearranged iCCA. They also highlight a toxicity profile dominated by on-target hyperphosphataemia.",{"name":70,"@type":61,"acceptedAnswer":71},"How does liquid biopsy contribute to understanding resistance?",{"text":72,"@type":64},"cfDNA-based liquid biopsy maps secondary kinase-domain mutations that underlie acquired resistance. This evidence informs the development of next-generation FGFR2-selective inhibitors and combination strategies, including EGFR/ERBB blockade.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353789,1790193710,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Drug Design, Development and Therapy  \nOpen Access Full Text Article REVIEW  \nFibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps  \nEnes Erul 1 , 2 , Sergio Cifuentes-Canaval 3 , Akhil Santhosh4 , Emir Sokolović 5 , Mario Della Mura 6 , Gerardo Cazzato 6 , Pınar Kubilay Tolunay 1 , 2 , *, Alessandro Rizzo 7 , *  \n1Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara University, Ankara, 06590, Türkiye; 2Ankara University Cancer Institute, Ankara University, Ankara, 06590, Türkiye; 3Cancer Institute – The Americas Clinic – AUNA, Medellín, Colombia; 4MVR Cancer Centre and Research Institute, Kozhikode, Kerala, India; 5Clinic of Oncology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina; 6Section of Molecular Pathology, Department of Precision and Regenerative Medicine and Ionian Area (Dimepre-J), University of Bari “aldo Moro”, Bari, 70124, Italy; 7S.S. D. C.O. r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, 70124, Italy  \n*These authors contributed equally to this work  \nCorrespondence: Alessandro Rizzo, S.S.D. C.O. r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, 70124, Italy, Email [rizzo.alessandro179@gmail.com](rizzo.alessandro179@gmail.com)  \n\n| Abstract: Fibroblast growth factor receptor 2 (FGFR2) alterations have emerged as an important targetable oncogenic driver ina biologically distinct subset of biliary tract cancers (BTCs), particularly intrahepatic cholangiocarcinoma (iCCA), alongside other actionable genomic events such as IDH1 mutations, BRAF V600E, HER2 amplification and MSI-H. FGFR2 fusions and mutations define a distinct molecular subgroup whose prevalence varies across geographic regions and etiologic backgrounds such as liver fluke– associated disease. Clinical studies of both reversible and irreversible FGFR inhibitors have demonstrated meaningful activity in FGFR2-rearranged iCCA, while also highlighting a characteristic toxicity profile dominated by on-target hyperphosphataemia. Parallel translational work using cfDNA-based liquid biopsy has mapped a spectrum of secondary kinase-domain mutations that underlie acquired resistance, informing the development of next-generation FGFR2-selective inhibitors (eg, lirafugratinib) and combination strategies with EGFR/ERBB blockade. Collectively, these data underscore the need for comprehensive molecular profiling and innovative umbrella trial designs to optimise targeted therapy in this rare, biologically heterogeneous malignancy.\u003Cbr>Keywords: intrahepatic cholangiocarcinoma, FGFR2 alterations, biliary tract cancer, FGFR inhibitors, acquired resistance, liquid biopsy |\n| --- |\n| Introduction\u003Cbr>Cholangiocarcinoma (CCA) constitutes a heterogeneous group of aggressive malignancies arising from the biliary tree epithelium. Anatomically, these tumors are classified into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes, with iCCA comprising 10–20% of cases, while perihilar and distal lesions account for approximately 50% and 30–40%, respectively.1,2 Although CCA represents only about 3% of all gastrointestinal malignancies worldwide, its clinical burden is disproportionately high due to late-stage diagnosis and limited therapeutic options.1\u003Cbr>The epidemiology of CCA exhibits marked geographic variation. In high-income Western countries, age-adjusted incidence rates range from 0.35 to 2 cases per 100,000 .1 In contrast, rates soar to 80–100 per 100,000 in endemic regions of East Asia, particularly Thailand, driven by the prevalence of liver fluke infections (Opisthorchis viverrini and Clonorchis sinensis) .3 Notably, the incidence of iCCA has risen alarmingly in Western populations over the past four decades, with a reported 165% increase in the United States alone.4 Despite advances in oncology, the prognosis remains |\n\n[https://doi.o","cbCaiccbWayPRbfc","https://ap.wps.com/l/cbCaiccbWayPRbfc","pdf",1678718,21,"English","# Abstract\n# Introduction\n# Epidemiology and clinical burden\n# Systemic treatment background","[{\"question\":\"What makes FGFR2 alterations important in biliary tract cancers?\",\"answer\":\"FGFR2 alterations function as a targetable oncogenic driver in a biologically distinct subset of biliary tract cancers, especially intrahepatic cholangiocarcinoma (iCCA). FGFR2 fusions and mutations define a specific molecular subgroup.\"},{\"question\":\"How have FGFR inhibitors performed in FGFR2-rearranged iCCA?\",\"answer\":\"Clinical studies of reversible and irreversible FGFR inhibitors demonstrate meaningful activity in FGFR2-rearranged iCCA. They also highlight a toxicity profile dominated by on-target hyperphosphataemia.\"},{\"question\":\"How does liquid biopsy contribute to understanding resistance?\",\"answer\":\"cfDNA-based liquid biopsy maps secondary kinase-domain mutations that underlie acquired resistance. This evidence informs the development of next-generation FGFR2-selective inhibitors and combination strategies, including EGFR/ERBB blockade.\"}]","Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma - Key Therapeutic Developments and Knowledge Gaps | PDF",1790107257,53,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d3b4abb83e84b984ddd8e0dbf4d186f.webp",983,1272,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/000b27bb0daebf06c6e1cf8dd492135d.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3adf5412262e5bb50b3cda7cb9a56ecd.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af465dc38a0370140f13b18e26f23338.webp",980,756]